DIAGNOS Provides Additional Information on Amendment to Convertible Debentures

Core Viewpoint - Diagnos Inc. is amending its convertible debentures, which involves an insider transaction that is exempt from certain regulatory requirements due to its limited impact on the company's market capitalization [2][3]. Group 1: Convertible Debentures Amendment - The amendment involves two convertible debentures owned by insider Mr. André Larente, with a nominal aggregate value of $20,000 [2]. - If converted, Mr. Larente would hold 2,188,115 Common Shares, representing 2.15% of the total issued Common Shares on a partially diluted basis [2]. - The amendment is exempt from valuation and minority approval requirements under MI 61-101, as the related party's participation does not exceed 25% of the company's market capitalization [2]. Group 2: Corporate Overview - Diagnos Inc. specializes in early detection of ophthalmic health issues using AI technology to enhance diagnostic accuracy and improve patient outcomes [4]. - The company is publicly traded and aims to provide valuable information to healthcare clinicians globally [4].